Perry C. Siatis - 17 Oct 2022 Form 3 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, GC and Secretary
Signature
Steven L. Scrogham, attorney-in-fact for Perry C. Siatis
Issuer symbol
ABBV
Transactions as of
17 Oct 2022
Net transactions value
$0
Form type
3
Filing time
27 Oct 2022, 17:01:31 UTC
Next filing
21 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABBV Common Stock, $0.01 par value 10,377 17 Oct 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ABBV Option (Right to buy) 17 Oct 2022 Common Stock 7,364 $93.50 Direct F2
holding ABBV Option (Right to buy) 17 Oct 2022 Common Stock 7,039 $105.92 Direct F3
holding ABBV Option (Right to buy) 17 Oct 2022 Common Stock 8,756 $144.54 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities represent restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. They vest in full on February 17, 2025, and include the right to have stock withheld for tax purposes.
F2 Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,365 shares on 2/20/2021 and as to 7,365 shares on 2/20/2022, and will become exercisable as to 7,364 shares on 2/20/2023.
F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 3,250 shares on 2/18/2022, and will become exercisable as to 3,250 shares on 2/18/2023 and as to 3,519 shares on 2/18/2024.
F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 2,919 shares on 2/17/2023, as to 2,919 shares on 2/17/2024 and as to 2,918 shares on 2/17/2025.